SAN FRANCISCO, May 15, 2019-- Phil Inc., an end-to-end technology platform for distributing and managing specialty prescription drugs, today announced the close of the company's Series B $25MM funding round led by new investor GreatPoint Ventures, with support from Tarsadia Investments, Crosslink Capital and Uncork Capital. The funding will fuel company growth, with a focus on hiring technical talent and expanding geographic footprint. Specialty medications treat complex conditions such as rheumatoid arthritis and HIV. In today's world, patients who take specialty medications, their physicians and pharmacies are beleaguered by antiquated communication models and manual workflows.